Itopride: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Malaysia prescribing information.

Generic Medicine Info

Indications and Dosage

Oral
Disorders associated with reduced gastrointestinal motility

Adult: For the management of gastrointestinal symptoms including the feeling of swollen abdomen, early satiety, postprandial fullness, upper abdominal pain or discomfort, nausea and vomiting, anorexia, and heartburn; non-ulcer dyspepsia: 50 mg tid. May reduce dose depending on the patient's age and symptoms.

Contraindications

Conditions when increased gastrointestinal motility may be harmful (e.g. gastrointestinal haemorrhage, mechanical obstruction or perforation).

Special Precautions

Elderly. Pregnancy and lactation.

Adverse Reactions

Significant: May cause cholinergic effects.
Gastrointestinal disorders: Abdominal pain, diarrhoea, salivary hypersecretion.
Investigations: Increased ALT, decreased WBC count.
Nervous system disorders: Dizziness, headache.
Skin and subcutaneous tissue disorders: Rash.

Drug Interactions

May reduce activity with anticholinergic agents.

Action

Description:
Mechanism of Action: Itopride is a gastroprokinetic agent. It increases acetylcholine concentrations by antagonising dopamine D₂ receptors and inhibiting acetylcholinesterase, thereby promoting gastrointestinal motility.
Pharmacokinetics:
Absorption: Rapidly and almost completely absorbed from the gastrointestinal tract. Bioavailability: 60%. Time to peak plasma concentration: 0.5-0.75 hours.
Distribution: Plasma protein binding: Approx 96%, mainly to albumin.
Metabolism: Extensively metabolised in the liver mainly via flavine monooxygenase enzymes.
Excretion: Via urine. Terminal elimination half-life: Approx 6 hours.

Chemical Structure

Storage

Store below 30°C. Protect from light and moisture.

MIMS Class

GIT Regulators, Antiflatulents & Anti-Inflammatories

ATC Classification

A03FA07 - itopride ; Belongs to the class of propulsives. Used in the treatment of functional gastrointestinal disorders.

References

Anon. Itopride. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 14/04/2021.

Buckingham R (ed). Itopride Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 14/04/2021.

Elthon 50 mg Tablets (Abbott Laboratories Ltd.). MIMS Thailand. http://www.mims.com/thailand. Accessed 14/04/2021.

Ganaton 50 mg Tablets (Abbott Laboratories [M] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 14/04/2021.

Progit 50 mg Tablets (PharmEng Technology Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 14/04/2021.

Disclaimer: This information is independently developed by MIMS based on Itopride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com